DHR|Analyst Targets
DHR|Company Info
DHR|Insider Trading
DHR|Fundamentals
DHR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.92 | - | - |
| Q2'26 | $2.06 | $1.94 | -5.8% |
| Q1'26 | $1.86 | $2.06 | +11.0% |
| Q4'25 | $2.17 | $2.23 | +2.6% |
| Q3'25 | $1.72 | $1.89 | +9.8% |
| Q2'25 | $1.64 | $1.80 | +9.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.6B | - | - |
| Q2'26 | $6.2B | $6.3B | +1.7% |
| Q1'26 | $6.1B | $6.0B | -2.9% |
| Q4'25 | $6.9B | $6.8B | -0.5% |
| Q3'25 | - | $6.1B | - |
| Q2'25 | - | $5.9B | - |
DHR|Monthly Returns
Market Data
DHR Stock Snapshot
- Market cap
- 157.03B
- P/E ratio
- 39.2
- Day range
- $222.74 – $227.86
- News sentiment
- 66/100 · Bullish
- Analyst target
- $241.91 (+7.6%)
- Consensus
- Buy · 34 analysts
Neither side has the upper hand on DHR right now, and its momentum ranks near the middle of DailyIQ's universe. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into DHR?
At today's price, Danaher Corporation needs to grow free cash flow about 18.6% a year for the next 10 years to justify its valuation at a 8.54% cost of capital. Over its actual history it has compounded free cash flow at 8.4% a year, so the market is asking for 10.1 percentage points above its own delivered rate. On that basis DHR looks priced above what its own growth record supports.
- Implied FCF growth
- 18.6%
- Historical FCF CAGR
- 8.4%
- Growth gap
- +10.1 pts
- Verdict
- RICH
- Discount rate (WACC)
- 8.54%
- Beta
- 0.83
Behaviour On Record
What DHR's own history says about today's numbers
- Realized volatility (21d)
- 29.0% 80th pct
- Below its peak
- -24.0%
- vs 200-day average
- +11.2%
- Up days (1y)
- 51%
Danaher Corporation is currently running 29.0% annualised volatility over the last 21 sessions. Measured against DHR's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 20.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
DHR is trading -24.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -14.0%, and the deepest was -30.9% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +11.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 77th percentile — a somewhat wider gap than its own norm. Over the past year DHR closed higher on 51% of sessions, and it is currently 4 sessions into a rising streak.
On October specifically: over 14 years of records, DHR finished the month higher 9 of 14 times, with a median return of +2.3% and an average of +0.5%. Its strongest month historically has been July at +4.7% on average, its weakest February at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: DHR has opened more than 2% away from the prior close in 74 of 3,268 sessions (2.3% of the time), with the largest gaps running +14.7% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, DHR moved an average of 2.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.8% and a largest of -5.6%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against DHR's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of DHR's sector?
Danaher Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on DHR?
Morgan Stanley most recently reiterated its rating on Danaher Corporation to Overweight on Oct 13, 2026 with a price target of $240 (from $220). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Morgan Stanley — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did Danaher Corporation's latest earnings release say?
Most important lines
- 1
Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance.
Guidance raised - 2
Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.
New this quarter - 3
Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.
New this quarter
Peers & ETF holders
DHR peers & ETF holders
Diagnostics & ResearchMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 60,978,360 | 8.70% | $13.96B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 55,084,630 | 7.86% | $10.49B | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 29,540,895 | 4.21% | $5.63B | 2026-08-13 |
| Wellington Management Group LLP | ▲ Buy | 16,316,834 | 2.33% | $3.11B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 14,280,335 | 2.04% | $2.71B | 2026-08-12 |
| JPMorgan Chase & Co | ▼ Sell | 12,185,400 | 1.74% | $2.35B | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 11,348,958 | 1.62% | $2.16B | 2026-08-13 |
| Capital Research Global Investors | ▲ Buy | 10,818,030 | 1.54% | $2.06B | 2026-08-12 |
| Norges Bank | ▲ Buy | 9,537,906 | 1.36% | $1.82B | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 6,925,441 | 0.99% | $1.32B | 2026-08-13 |
| Janus Henderson Group plc | ▼ Sell | 6,489,965 | 0.93% | $1.22B | 2026-05-18 |
| Goldman Sachs Group Inc | ▲ Buy | 5,364,861 | 0.77% | $1.02B | 2026-08-14 |
| Bank of America Corp | ▼ Sell | 5,217,586 | 0.74% | $993.85M | 2026-08-14 |
| Fisher Asset Management, LLC | ▼ Sell | 4,484,774 | 0.64% | $854.26M | 2026-08-04 |
| Invesco Ltd. | ▼ Sell | 3,955,992 | 0.56% | $753.54M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 2,641,746 | 0.38% | $503.20M | 2026-08-14 |
| D1 Capital Partners L.P. | ▼ Sell | 2,282,039 | 0.33% | $434.68M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 2,140,587 | 0.31% | $407.74M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 2,107,482 | 0.30% | $401.43M | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 1,853,198 | 0.26% | $353.10M | 2026-08-13 |
| Glenview Capital Management, LLC | ▲ Buy | 1,145,979 | 0.16% | $218.29M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 1,121,640 | 0.16% | $213.65M | 2026-08-12 |
| Citadel Advisors LLC | ▼ Sell | 943,694 | 0.13% | $179.75M | 2026-09-02 |
| Citigroup Inc | ▲ Buy | 778,298 | 0.11% | $148.25M | 2026-08-03 |
| Renaissance Technologies LLC | ▲ Buy | 760,636 | 0.11% | $144.89M | 2026-08-13 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Kevin Hern | House | OK01 | ▼ Sell | $1K - $15K | 2026-09-02 | 2026-09-25 |
| Kevin Hern | House | OK01 | ▼ Sell | $15K - $50K | 2026-08-31 | 2026-09-25 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-10-07 | 2025-11-14 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-09-25 | 2025-10-22 |
| Thomas H. Kean | House | NJ07 | ▲ Buy | $1K - $15K | 2025-09-03 | 2025-10-14 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $1K - $15K | 2025-08-28 | 2025-09-03 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-07-22 | 2025-08-13 |
| Pete Sessions | House | TX17 | ▼ Sell | $50K - $100K | 2025-06-12 | 2025-06-21 |
| Thomas H. Kean | House | NJ07 | ▲ Buy | $1K - $15K | 2025-06-11 | 2025-07-16 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2025-04-28 | 2026-01-13 |
| Bruce Westerman | House | AR04 | ▼ Sell | $1K - $15K | 2025-04-21 | 2025-05-12 |
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2025-04-11 | 2025-05-16 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $15K - $50K | 2025-04-08 | 2025-05-08 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Greg Landsman | House | OH01 | ▼ Sell | $1K - $15K | 2025-03-27 | 2025-04-08 |
| Bruce Westerman | House | AR04 | ▲ Buy | $1K - $15K | 2025-03-04 | 2025-04-16 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-02-26 | 2025-03-06 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $15K - $50K | 2025-02-25 | 2025-03-27 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-01-15 | 2025-02-12 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |